




RealRate

PHARMACEUTICAL 2024

Avadel Pharmaceuticals PLC
Rank 185 of 309



The relative strengths and weaknesses of Avadel Pharmaceuticals PLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avadel Pharmaceuticals PLC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 26% points. The greatest weakness of Avadel Pharmaceuticals PLC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 67% points.

The company's Economic Capital Ratio, given in the ranking table, is 167%, being 46% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	134,202
Cost of Goods Sold	846
Intangible Assets	16,836
Liabilities, Current	36,855
Liabilities, Non-Current	7,344
Other Assets	13,075
Other Compr. Net Income	3,174
Other Expenses	9,385
Other Liabilities	32,760
Other Net Income	-13,042
Other Revenues	27,963
Property and Equipment	585
Research and Development	13,261
Selling, General and Administrative Expense	151,705

Output Variable	Value in 1000 USD
Assets	164,698
Liabilities	76,959
Expenses	175,197
Revenues	27,963
Stockholders Equity	87,739
Net Income	-160,276
Comprehensive Net Income	-158,689
BaseVar	230,516
ECR before LimitedLiability	27%
Economic Capital Ratio	167%